Cargando…
Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial
BACKGROUND: Elevated levels of osteoprotegerin, a secreted tumor necrosis factor–related molecule, might be associated with adverse outcomes in patients with coronary artery disease. We measured plasma osteoprotegerin concentrations on hospital admission, at discharge, and at 1 and 6 months after di...
Autores principales: | Ueland, Thor, Åkerblom, Axel, Ghukasyan, Tatevik, Michelsen, Annika E., Aukrust, Pål, Becker, Richard C., Bertilsson, Maria, Himmelmann, Anders, James, Stefan K., Siegbahn, Agneta, Storey, Robert F., Kontny, Frederic, Wallentin, Lars |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850148/ https://www.ncbi.nlm.nih.gov/pubmed/29330256 http://dx.doi.org/10.1161/JAHA.117.007009 |
Ejemplares similares
-
Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) Trial
por: Gregersen, Ida, et al.
Publicado: (2020) -
Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy
por: Sumaya, Wael, et al.
Publicado: (2018) -
Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial
por: Åkerblom, Axel, et al.
Publicado: (2019) -
Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study
por: Sumaya, Wael, et al.
Publicado: (2020) -
Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y(12) Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial
por: Franchi, Francesco, et al.
Publicado: (2019)